Biosimilars Market to Exceed US$85 Billion Valuation by 2031: TMR Study Notes

  • The demand for recombinant proteins without glycosylation in the biosimilars market is increasing due to the need for advanced and affordable treatments for chronic diseases in the world; application of advanced technologies to broaden the avenues
  • Expiration of patents on several important biologic drugs to drive revenue potential in biosimilar production; Europe has emerged as a remarkably lucrative market and will continue to witness profitable opportunities

ALBANY, NY, June 13, 2022 /PRNewswire/ — The market value of biosimilars is steadily increasing due to their growing acceptance around the world in the management of chronic and life-threatening conditions. Advances in biotechnology have enabled pharmaceutical companies to derive revenue from an increasing number of product approvals, particularly in oncology. A study by TMR has forecast that the global biosimilars market valuation will grow at a CAGR of 15.5% during the period 2022-2031.

Healthcare professionals are showing increased interest in prescribing biosimilars due to their desire to increase access to biologic therapies for their patients, thereby driving sales of biosimilar market products. Biosimilars have proven to be essential in reducing healthcare costs in the management of a wide range of chronic diseases, biosimilars market key insights reiterate. Along with wider access to treatments, the cost factor will be crucial in guiding the shift from biologics to biosimilars, which will greatly increase the market share of biosimilars.

A favorable regulatory landscape, especially with regard to regular updates of product-specific directives, especially in Europe pivoted the rapidly changing biosimilars market. These trends are catalyzing product penetration. It should be noted that biosimilar monoclonal antibodies are widely used in the treatment of cancer and rheumatoid arthritis, thereby generating profitable opportunities in the biosimilars market.

Request Biosimilars Market Research Report Brochure –

Key Findings from the Biosimilars Market Study

  • Biosimilar companies will derive substantial revenue from cancer care: Biosimilar producers aim to exploit the vast revenue potential of oncology drugs. The high cost of biologics has hampered access to therapies in cancer management. The need for new immunotherapy drugs has strongly driven the development of biosimilars for oncology, observed the TMR study on the biosimilar market.
  • The need to reduce costs in chronic disease management opens up huge market opportunities for pharmaceutical companies: The prospect of biosimilars for a wide range of chronic diseases has grown. This is partly due to the remarkable safety and effectiveness of these in their management. The demand for biosimilar drugs is likely to increase in diabetes, hypertension, respiratory diseases, obesity, arthritis, gastrointestinal diseases. The unmet need for these due to high cost will catalyze product sales in the biosimilars market.
  • Producers will benefit from investments in recombinant proteins without glycosylation: The TMR study revealed that a growing number of companies in the biosimilars market are seeing an incredible opportunity to add value to recombinant proteins without glycosylation. As a result, R&D funding on these is expected to increase rapidly over the forecast period.

Request Biosimilars Market Research Report Brochure –

Biosimilars Market: Key Drivers

  • Leading pharmaceutical companies are leveraging evidence from clinical data to support their claims regarding efficacy, side effect risk profile and product quality, which continue to play a key role in expanding the market for biosimilars.
  • The increasing number of originator biologics that are no longer patented or losing data exclusivity and market exclusivity is likely to drive healthcare professionals and patients to switch from biologics to biosimilars in the years to come. coming. The factor will increasingly define the contours of biosimilar market development.

Get Exclusive Sample PDF Copy of Biosimilars Market Report –

Biosimilars market: regional growth momentum

Europe held a large and substantial share of the global biosimilars market in 2021. Huge revenue streams in the regional market were fueled by strong licensing pathways and increased spending on biosimilar drugs. A significant number of licensees to date have also worked on behalf of pharmaceutical companies seeking to profit from their investments in the Europe biosimilars market. A large number of biosimilars approved for various active substances in the EU will continue to propel lucrative growth for industry players Europe biosimilars market.

Biosimilars market: key players

Some of the major players in the industry are Apotex Inc., STADA Arzneimittel AG, Amgen, Inc., Celltrion Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Biocon, Intas Pharmaceuticals Ltd. and Pfizer, Inc.

Inquire Before You Buy –

Segmentation of the biosimilars market

  • Product
    • Recombinant glycosylated proteins
      • Monoclonal antibodies
      • Erythropoietin
      • Others
    • Recombinant non-glycosylated proteins
      • Insulin
      • Granulocyte Colony Stimulating Factor
      • Recombinant human growth factor
      • interferons
    • Recombinant peptides
  • Indication
    • Chronic diseases
    • Oncology
    • Autoimmune diseases
    • Infectious diseases
    • Blood disorders
    • Growth hormone deficiency
    • Others

Regions covered

  • North America
  • Latin America
  • Europe
  • Latin America
  • Middle East & Africa


  • WE
  • Canada
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC countries
  • South Africa

Modernization of healthcare in terms of infrastructure and services has pushed the healthcare industry to new heights, stay updated with Latest Health Industry Research Reports by Transparency Market Research:

Plasma Protein Therapeutics Market: Growing investment in innovation, increasing demand for immunoglobulin (IG), increasing indications and therapeutic use of plasma-derived protein therapeutics are expected to drive the protein therapeutics market plasma.

Recombinant Plasma Protein Therapeutics Market: The global Recombinant Plasma Protein Therapeutics market is driven by various factors such as the shift in the use of plasma-derived proteins to recombinant therapies, increased awareness in the management of rare diseases and the increased emphasis on investments in rare diseases.

Fish Collagen Peptides Market: The global fish collagen peptides market was valued at ~US$250 million in 2018. The Fish Collagen Peptides Market is expected to reach ~500 million USD by 2027, expanding at a CAGR of approximately 8% from 2019 to 2027.

Peptide Therapeutics Market: High incidence and prevalence of metabolic disorders to accelerate the growth of the global peptide therapeutics market. Additionally, advancements in drug delivery and bioavailability are expected to drive the global peptide therapies market over the forecast period.

Collagen Peptides and Gelatin Market: Rising commercialization of novel collagen-based drug delivery systems and rising social awareness for personal wellness is expected to drive the global collagen peptides market and gelatin. The global collagen peptides and gelatin market is expected to grow at a CAGR of 8.7% from 2019 to 2027.

Insulin Delivery Devices Market: Rising incidence of diabetes has driven the demand for minimally invasive devices for intravenous delivery of insulin into the body. This, in turn, is driving the insulin delivery device market. The global insulin delivery devices market is expected to reach a market value of US$21,783.3 million until 2026.

Autoimmune Disease Diagnostics Market: High Prevalence of Autoimmune Diseases Globally, Rising Global Healthcare Expenditures, Growing People’s Awareness of Autoimmune Diseases is Expected to Drive the Global Autoimmune Disease Diagnostics Market during the forecast period.

Antihypertensive drugs market: increase in the launch of new drugs and diagnostic agents; and key industry developments such as collaborations and establishment of new R&D centers are likely to propel the global antihypertensive drugs market.

About Us

Transparency Market Research is a global market information company that provides market research reports and services. Our proprietary blend of quantitative forecasting and trend analysis delivers forward-looking insights to thousands of decision makers. Our experienced team of analysts, researchers and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With broad research and analytical capability, Transparency Market Research uses rigorous primary and secondary research techniques to develop distinctive datasets and research material for trade reports.

For more information on research on leading industries, visit our YouTube channel and click subscribe for future update –

Contact us:
Rohit Bhisey
Transparency Market Research Inc.
1000 N. West Street,
Office 1200, Wilmington, Delaware 19801 United States
Tel: +1-518-618-1030
UNITED STATES – Canada toll-free: 866-552-3453
E-mail: [email protected]


SOURCE Transparency Market Research


About Author

Comments are closed.